BioAge Labs, Inc. (NASDAQ: BIOA) announced that the first participant has been dosed in QUELL-CV, a Phase 2 proof-of-concept clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE